Tag Archives: business

Hot Investor Mandate: Seed Stage Investment Firm Seeks Europe-Based Enabling Platforms, Diagnostics, Digital Health and More

21 Oct

A seed and early-stage venture investor and invests in disruptive technologies with focus on highly scalable Health Tech and ICT models. The typical investment size ranges from €0.5 million to € 5 million. The firm invests only in companies based in Europe. 
 
The firm is currently looking for new opportunities and focuses on companies developing biotech enabling platforms, diagnostics, digital health solutions and minimally to non/minimal-invasive medical devices. The firm will not invest in pure drug development companies without underlying platform technology. 
 
The firm typically seeks to invest in private companies with convincing founder teams. The firm will consider pre-revenue companies. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: VC Firm Invests €500K – 5M in Life Science Tools, Therapeutics, and Medtech in US and Europe

21 Oct

A venture capital fund makes equity investments ranging from €500,000 to €5 million, with additional capital reserved for follow-on financing. The firm invests in companies across Europe and selectively in the United States. 

The firm is currently seeking opportunities in the sectors of BioTools, Labtech, TechBio, Medical Technology, Biotech, and Diagnostics. The firm prefers companies that have already established proof of concept. 

The firm focuses on privately held companies and does not require high-profile management teams to be in place. The firm generally takes a board seat following investment and prefers to act as the lead investor. The firm targets companies that already have a commercially viable technology, product, or service, ideally with a first collaboration or pilot with a potential customer, and that can reach commercialization with total investment between €10 million and €50 million. 
 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

RESI London 2025: Dec 4! See feedback from previous attendees about the UK’s biggest investment conference!

21 Oct

By Sougato Das, President and COO, LSN

Sougato-Das

RESI London 2025 will be the second year of the UK’s biggest life science investor conference. We expect 250 investors, ready to finance your company. The RESI partnering system allows you to schedule face to face meetings with each investor. See what last year’s attendees are saying!

Testimonials

“RESI London was an extremely productive experience for my company, and the partnering system was so easy to use.”

– Nick Sireau, CEO, Serenatis Bio

“RESI is the go-to meeting for biotech CEOs’ seeking early stage capital. They have built an early stage platform educating founders and bringing capital to them. They are the only people serving this under loved sub sector with such passion.”

– Sunil Shah, CEO, O2h Ventures & Co-founder, O2h Group

“Attending RESI London for the first time was a refreshing and highly positive experience. The event exceeded my expectations in several ways. The atmosphere was welcoming and collaborative, which created a conducive environment for meaningful interactions. What stood out most was the exposure to a unique group of investors—those with a specific interest in early-stage, cutting-edge technologies. These are exactly the type of investors we aim to connect with at Rinri, so the conference provided an excellent platform to engage with individuals who understand the risks and rewards of innovative science-driven ventures.”

– Simon Chandler, CEO, Rinri Therapeutics

“My session was punctual and well-organized. The jury members were thoughtfully selected and provided insightful, constructive feedback that was highly valuable.”

– Christine Ruckenbauer, CBO, RIANA Therapeutics

“I highly value RESI and am grateful for the opportunity both to contribute as a pitch judge, company scouting and the networking opportunities. You have a dynamic network with easy, friendly, professional access. Thanks for all you are doing for the life science and tech development sector.”

– Jill Sorensen, MTEC (Investor)

“As One Nucleus seeks to enable our members to engage with the widest possible investor pool, partnering with RESI London creates a unique opportunity to bring our members into contact with new global early-stage investors to complement the known local investors they meet at all other early-stage pitching events in the UK.”

– Tony Jones, CEO, One Nucleus

“We started this as a grassroots meeting with One Nucleus, and it has been extremely gratifying and rewarding to see our international investors attending because the UK, we know, has some great science that needs to get to the global stage. We are expecting 250+ investors.”

– Dennis Ford, CEO, Life Science Nation

Register RESI London by Friday, October 24 to save £200 on early bird rates!

Register for RESI London Appy to Pitch at RESI London

Tags: , , , , , , , , , , , , , , , , , , ,

Confirmed Investors at RESI London 2025 

21 Oct

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Life Science Nation (LSN) is thrilled to announce the confirmed investors for RESI London 2025, taking place on December 4, at King’s Fund, 11 Cavendish Square, with virtual partnering on December 8–9. This premier event connects early-stage life science companies with a diverse array of global investors, facilitating meaningful partnerships and funding opportunities.

Meet the Confirmed Investors

RESI London 2025 will feature a robust lineup of investors spanning various sectors within the life sciences industry. Confirmed investors include:

This diverse group of investors represents a broad spectrum of interests, from pharmaceutical giants to specialized venture capital firms, ensuring that attendees have access to a wealth of expertise and potential funding sources.

Why Attend RESI London 2025?

RESI London 2025 provides an exceptional platform for early-stage companies to engage directly with top-tier investors across the life sciences industry, present innovations to a panel of esteemed judges in the Innovator’s Pitch Challenge (IPC), and receive valuable feedback. Attendees will have the opportunity to expand their network by building relationships with potential partners, collaborators, and industry experts, while also continuing discussions and meetings through virtual partnering on December 8–9, extending their reach and maximizing opportunities.

Whether you’re seeking funding, partnerships, or strategic alliances, RESI London 2025 provides the resources and connections necessary to propel your venture forward.

Register for RESI London >>

Tags: , , , , , , , , , ,

Make the Most of JPM Week with Sunday Partnering at the Marriott Marquis 

21 Oct

By Max Braht, Director of Business Development, LSN

Max-Braht-Headshot

JPM week is coming fast, and the best opportunities go to those who plan early. If you still haven’t secured a venue or partnering space, Life Science Nation (LSN) has your solution. As the host of RESI JPM, LSN is opening Sunday partnering at the Marriott Marquis, giving attendees an extra day to meet face-to-face with fellow RESI participants or connect informally outside the partnering system before the main event begins.

Sunday partnering provides a head start on the biggest week in healthcare investment, whether you’re scheduling investor meetings, gathering your team, or hosting your own private event. The Marriott Marquis is at the center of the JPM ecosystem, making it the perfect base for receptions, showcases, and partnering tables throughout the week.

If you represent a membership organization, this is your chance to give your members valuable exposure and a convenient home base in San Francisco—without the steep prices other hotels are charging for table rentals. And for product or service providers, sponsoring or exhibiting at RESI remains the most direct and cost-effective way to meet early-stage innovators. Unlike other partnering events, RESI’s community welcomes vendor meetings, and our partnering stats show that clearly.

Life Science Nation is here to help you make the most of the biggest week of the year. Whether you’re planning a private reception, setting up a partnering table, or joining RESI as an exhibitor, our team can help you build visibility, secure meetings, and connect with the early-stage life science community that gathers at JPM each January.

Register RESI JPM by Friday, October 24 to save $600 on early bird rates!

Register for RESI JPM >>

Tags: , , , , , , , , , , , , , , , , ,

Hot Investor Mandate: USA-Based VC Firm Invests Up to $20M With Strong Focus on Therapeutics, Open to Medical Devices and Diagnostics

15 Oct

A venture capital firm based in the US manages close to $1B assets under management. The firm is an active investor in both early and late-stage companies and typically makes investments ranging from $1M to over $20M, depending on the company’s stage of development. The firm is open to global investment opportunities. 
 

The firm is primarily focused on therapeutics but has also invested in medical devices and diagnostics, remaining open to opportunities across these sectors. Within therapeutics, the firm considers all modalities and indications but is currently most interested in gene therapy, gene editing, and technologies addressing central nervous system (CNS) diseases. The firm invests in both pre-clinical and clinical-stage opportunities. 

The firm does not have specific company or management team requirements. The firm generally prefers to lead investment rounds and seek board representation but has also participated as a co-investor in syndicates. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Strategic Corporate Venture Fund Invests in First-In-Class Novel Therapies, Engaging in Companies in Pre-IND Stage

15 Oct

A strategic corporate venture capital fund established by a full-fledged pharmaceutical company seeks to make equity investments in startup companies that discover and develop innovative therapeutic products and/or drug-enabling platform technologies with clear potential to benefit cancer patients. Investment size is flexible depending on the deal, and the firm will also consider option-type investments and spin-outs in addition to pure equity investments. The firm is currently seeking focusing on opportunities in USA and Europe. 

The firm considers early-stage (generally research to pre-IND) first-in-class or new biology-based approaches in drug discovery and innovative platform technologies, particularly assets that have a strategic fit with the parent company’s pipeline. The firm invests across a wide range of modalities, including biologics, oncolytic viruses, small molecules, and, on an opportunistic basis, cell and gene therapies. The firm’s primary indication of interest is oncology, but it also evaluates opportunities in immunology, allergy, musculoskeletal, and orphan indications. 

While the firm is primarily focused on therapeutics, it may selectively review technologies in the medical device, diagnostic, or digital health sectors if there is strong strategic alignment. 

The firm seeks management teams with strong sector expertise. Leveraging deep oncology drug discovery and development capabilities, the firm provides financial resources and strategic support to help translate novel research and high-potential drug candidates into cornerstone products. The firm may request regional options or rights on a case-by-case basis. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

← Older Entries
Newer Entries →